Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics ( (AU:ATH) ) just unveiled an update.
Alterity Therapeutics has appointed seasoned biotech executive Ann Cunningham as an independent Non-Executive Director, bolstering its Board as the company advances its lead drug candidate ATH434 toward Phase 3 development in Multiple System Atrophy. With more than 25 years of global pharmaceutical and biotech experience, including senior commercial roles at Eli Lilly and Teva and leadership of major neurodegenerative and psychiatry brands, Cunningham is expected to strengthen Alterity’s commercial strategy and patient-focused approach as it positions ATH434 for late-stage development and eventual commercialization, potentially enhancing value for shareholders and its standing in the neurodegenerative disease market.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative conditions, particularly Multiple System Atrophy and related Parkinsonian disorders. Its lead candidate, ATH434, has shown clinically meaningful efficacy in Phase 2 trials, and the company is preparing a pivotal Phase 3 study while also advancing a broader discovery platform for neurological diseases.
Average Trading Volume: 5,614,265
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.